Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders

This study is testing whether it is safe and feasible to reduce or stop a category of medications called anticholinergic medications (ACMs) in people with schizophrenia or other psychiatric disorders. These medications are often prescribed to manage movement side effects from antipsychotic drugs, but they can cause their own problems — including memory issues, dry mouth, and constipation. The study explores whether patients who are clinically stable can safely taper off these drugs. **You may be eligible if...** - You are 18 or older - You have a diagnosis of schizophrenia spectrum disorder, schizoaffective disorder, bipolar disorder, or another psychiatric illness - You have been taking both anticholinergic medications and antipsychotics for at least 6 months - You have been clinically stable for at least 3 months, as assessed by your care team - You are taking the anticholinergic medication specifically to manage movement side effects from antipsychotics - Examination shows that movement side effects are minimal or absent **You may NOT be eligible if...** - You still have significant movement side effects that require the medication - You have not been stable long enough - Your healthcare team determines the taper is not appropriate for you Talk to your doctor to see if this trial is right for you.